Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review.

Transl Lung Cancer Res · 2026 · PMC12877897 · PMID 41659274

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

A study in the US found that from 2015 to 2017, almost 60% of all PD-L1 testing used 22C3 (with an increasing trend from 39% at the start of the study to 68% in the fourth quarter of 2017) ( 32 ).

also in 63,971 other papers

a positive trendno p-value reported

The first pre-specified interim analysis used the SP263 assay and reported stratified OS HRs suggesting a positive trend favoring atezolizumab in PD-L1 subgroups: stage II–IIIA (n=882), HR 0.95 (95% CI: 0.74–1.24); stage II–IIIA PD-L1 TC ≥1% (n=476), HR 0.71 (95% CI: 0.49–1.03); and stage II–IIIA PD-L1 TC ≥50% (n=229), HR 0.43 (95% CI: 0.24–0.78) ( 35 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.